Literature DB >> 16151594

Spinal leptomeningeal metastases from prostate cancer.

R Deinsberger1, R Regatschnig, B Kaiser, H C Bankl.   

Abstract

OBJECTIVE: Prostate cancer is a well known cause of spinal column metastases; however, an intradural location is extremely rare. It is considered to be a type of leptomeningeal spread. Cerebral seeding has usually occurred by the time of presentation. Due to a poor prognosis, surgery is rarely indicated, and controversially discussed. PATIENT AND
RESULTS: We review the known cases of spinal leptomeningeal prostate cancer spread, including our patient, who developed paraparesis over 6 weeks, 3 years after prostate cancer was diagnosed. Following surgical decompression and resection, the patient additionally received radiation therapy of the spinal meninges and antihormonal treatment. Six months after surgery, the patient is still ambulatory with a good quality of life.
CONCLUSION: Spinal leptomeningeal metastases occur at a late stage of systemic disease, and the prognosis is generally poor. In literature, outcomes after surgery are reported as devastating, with mortality and morbidity rates of up to 20 and 60%. The aim of surgery is to relieve pain, preserve or even restore neurological function, and reveal histology if uncertain. This may be achieved by debulking the tumor without placing the patient at an unacceptably high risk. Surgery should be performed in selected cases of spinal leptomeningeal metastases, in patients who are still ambulatory with controlled systemic disease, and should be followed by adjuvant therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16151594     DOI: 10.1007/s11060-005-7284-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  17 in total

Review 1.  Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part II: individual countries.

Authors:  M Quinn; P Babb
Journal:  BJU Int       Date:  2002-07       Impact factor: 5.588

Review 2.  The surgical treatment of metastatic spinal tumors within the intradural extramedullary compartment.

Authors:  T S Chow; I E McCutcheon
Journal:  J Neurosurg       Date:  1996-08       Impact factor: 5.115

3.  Cancer statistics, 1999.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1999 Jan-Feb       Impact factor: 508.702

4.  Adenocarcinoma of the prostate and metastatic medullary compression. A retrospective study of 22 patients.

Authors:  M Honnens de Lichtenberg; E Kvist; P Hjortberg; A Karle
Journal:  Scand J Urol Nephrol       Date:  1992

5.  Intradural and extradural spinal metastases.

Authors:  U Schick; G Marquardt; R Lorenz
Journal:  Neurosurg Rev       Date:  2001-03       Impact factor: 3.042

6.  Intradural extramedullary spinal canal secondary neoplasms: MR findings in 30 patients.

Authors:  I Frey; C Le Breton; A Lefkopoulos; N Perrot; A Khalil; J Chopier; A Le Blanche; J M Bigot
Journal:  Eur Radiol       Date:  1998       Impact factor: 5.315

7.  Metastatic prostate carcinoma to the intradural extramedullary spinal compartment. Case report.

Authors:  Stephen J Hentschel; Ehud Mendel; Sanjay Singh; Laurence D Rhines
Journal:  J Neurosurg       Date:  2004-04       Impact factor: 5.115

8.  Characteristics of spinal cord compression in adenocarcinoma of prostate.

Authors:  D A Kuban; A M el-Mahdi; S V Sigfred; P F Schellhammer; T J Babb
Journal:  Urology       Date:  1986-11       Impact factor: 2.649

9.  Intradural extramedullary spinal metastasis from an ovarian carcinoma.

Authors:  R Mehrotra; K Sharma
Journal:  Indian J Cancer       Date:  2002 Oct-Dec       Impact factor: 1.224

10.  Management of vertebral metastases in prostate cancer: a retrospective analysis in 119 patients.

Authors:  Luis E Cereceda; Aude Flechon; Jean-Pierre Droz
Journal:  Clin Prostate Cancer       Date:  2003-06
View more
  1 in total

Review 1.  Leptomeningeal metastases from prostate cancer: an emerging clinical conundrum.

Authors:  George Orphanos; Alexandros Ardavanis
Journal:  Clin Exp Metastasis       Date:  2009-11-11       Impact factor: 5.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.